BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, Scott BL, Woszczyk D, Koschmieder S, García-Delgado R, László R, McGreivy JS, Rothbaum WP, Kiladjian JJ.
Verstovsek S, et al. Among authors: laszlo r.
Future Oncol. 2022 Nov 23. doi: 10.2217/fon-2022-0901. Online ahead of print.
Future Oncol. 2022.
PMID: 36416118
Free article.
Review.